RxDoctor Payments Data

Kacie Teeter, PA

Medical · Statesville, NCNPI 1063567626

Payments from drug & device makers

$1,195in general payments, 2019–2025

Across 69 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$354
  • AstraZeneca$132
  • Inspire Medical Systems, Inc.$130
  • Abbott$129
  • Lilly USA, LLC$98
  • Dexcom, Inc.$75
  • plus $277 from 10 others

What the payments were for

  • Food & beverage$1,195100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,195 in reported general payments places this provider in the 65th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$48,524
Medicare patients
174
Services billed
667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol72$52,688
OzempicSemaglutide35$30,700
RybelsusSemaglutide25$27,410
JardianceEmpagliflozin29$17,583
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$14,019
Tresiba Flextouch U-100Insulin Degludec21$13,510
MyrbetriqMirabegron28$12,456
EliquisApixaban13$8,130
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,154
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$6,040
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$5,368
SynthroidLevothyroxine Sodium59$5,120
Breo ElliptaFluticasone/Vilanterol11$4,409
Levemir FlexpenInsulin Detemir13$2,844
Atorvastatin Calcium264$2,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$132$59,84385 claims
Novo NordiskOzempic, Rybelsus$354$58,11060 claims
Astellas Pharma US IncMyrbetriq$18$12,45628 claims
PfizerEliquis$67$8,13013 claims
AbbVieSynthroid$45$5,12059 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 878 medical providers in North Carolina.

Other medical in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →